An alternative to donor blood for transfusion or as a source of autologous blood for patients with rare blood types

About

We are developing a system that is capable of mass manufacturing mature red blood cells either as an alternative to donor blood for transfusion or as a source of autologous blood for patients with rare blood types. The technology has demonstrated proof of principle and is undergoing scale up. Patented, it is available for commercialisation. When contacting us, please quote reference number 5396.

Register for free for full unlimited access to all innovation profiles on LEO

  • Discover articles from some of the world’s brightest minds, or share your thoughts and add one yourself
  • Connect with like-minded individuals and forge valuable relationships and collaboration partners
  • Innovate together, promote your expertise, or showcase your innovations